Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model.
暂无分享,去创建一个
Patrick D. Halley | J. Byrd | C. Castro | C. Kural | M. Webber | D. Lucas | C. R. Lucas | Emily Mcwilliams | R. A. Patton | P. Halley
[1] M. Reggiani,et al. ON PHYSICO-CHEMICAL INTERACTIONS BETWEEN DAUNOMYCIN AND NUCLEIC ACIDS. , 1965, Biochimica et biophysica acta.
[2] A. Marco. Mechanism of action of daunomycin. , 1967 .
[3] S. Siegel,et al. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. , 1976, Cancer research.
[4] S. Collins,et al. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture , 1977, Nature.
[5] S. Collins,et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia , 1979 .
[6] S. Martin. Absorption and circular dichroic spectral studies on the self‐association of daunorubicin , 1980, Biopolymers.
[7] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[8] D. Marquardt,et al. Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. , 1990, Cancer research.
[9] John Calvin Reed,et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells , 1997, Leukemia.
[10] A. Garnier-Suillerot,et al. Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study. , 1998, Biochimica et biophysica acta.
[11] M. Baccarani,et al. P‐glycoprotein (PGP), lung resistance‐related protein (LRP) and multidrug resistance‐associated protein (MRP) expression in acute promyelocytic leukaemia , 2000, British journal of haematology.
[12] K. Bhalla,et al. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). , 2000, Blood.
[13] N. Seeman. DNA in a material world , 2003, Nature.
[14] Glen E Kellogg,et al. Hydropathic analysis of the free energy differences in anthracycline antibiotic binding to DNA. , 2003, Nucleic acids research.
[15] Matthias John,et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.
[16] A. Anagnostopoulos,et al. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia , 2005, Leukemia & lymphoma.
[17] Ulrich Beyer,et al. Liposomal encapsulated anti-cancer drugs. , 2005, Anti-cancer drugs.
[18] P. Rothemund. Folding DNA to create nanoscale shapes and patterns , 2006, Nature.
[19] Thomas S. Lin,et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. , 2007, Blood.
[20] James R Heath,et al. Nanotechnology and cancer. , 2008, Annual review of medicine.
[21] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[22] Yamuna Krishnan,et al. A DNA nanomachine that maps spatial and temporal pH changes inside living cells. , 2009, Nature nanotechnology.
[23] Soong Ho Um,et al. Multifunctional nanoarchitectures from DNA-based ABC monomers , 2009, Nature nanotechnology.
[24] Shawn M. Douglas,et al. Multilayer DNA origami packed on a square lattice. , 2009, Journal of the American Chemical Society.
[25] Shawn M. Douglas,et al. Self-assembly of DNA into nanoscale three-dimensional shapes , 2009, Nature.
[26] Adam H. Marblestone,et al. Rapid prototyping of 3D DNA-origami shapes with caDNAno , 2009, Nucleic acids research.
[27] H. Dombret,et al. An old AML drug revisited. , 2009, The New England journal of medicine.
[28] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[29] Kersten S. Rabe,et al. Orthogonal protein decoration of DNA origami. , 2010, Angewandte Chemie.
[30] F. Gao,et al. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells , 2010, International journal of nanomedicine.
[31] Joseph M. DeSimone,et al. Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.
[32] H. Pei,et al. Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides. , 2011, ACS nano.
[33] Dong-Ming Huang,et al. Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy. , 2011, ACS nano.
[34] M. Jensen,et al. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia , 2012, Cancer Chemotherapy and Pharmacology.
[35] Tim Liedl,et al. Cellular immunostimulation by CpG-sequence-coated DNA origami structures. , 2011, ACS nano.
[36] M. Grever,et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Mark Bathe,et al. A primer to scaffolded DNA origami , 2011, Nature Methods.
[38] Tim Liedl,et al. DNA origami-templated growth of arbitrarily shaped metal nanoparticles. , 2011, Small.
[39] T. G. Martin,et al. Rapid Folding of DNA into Nanoscale Shapes at Constant Temperature , 2012, Science.
[40] Mingfei Yao,et al. A physical model for the size-dependent cellular uptake of nanoparticles modified with cationic surfactants , 2012, International journal of nanomedicine.
[41] Daniel G. Anderson,et al. Molecularly Self-Assembled Nucleic Acid Nanoparticles for Targeted In Vivo siRNA Delivery , 2012, Nature nanotechnology.
[42] M. Dewhirst,et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. , 2012, Cancer research.
[43] Shawn M. Douglas,et al. A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads , 2012, Science.
[44] Andrew Emili,et al. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. , 2012, Journal of the American Chemical Society.
[45] Björn Högberg,et al. DNA origami delivery system for cancer therapy with tunable release properties. , 2012, ACS nano.
[46] Hao Yan,et al. DNA origami as a carrier for circumvention of drug resistance. , 2012, Journal of the American Chemical Society.
[47] Robert Langer,et al. Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.
[48] Matthieu Wilhelm,et al. Multistep drug intercalation: molecular dynamics and free energy studies of the binding of daunomycin to DNA. , 2012, Journal of the American Chemical Society.
[49] Sanjiv S Gambhir,et al. Nanooncology: The future of cancer diagnosis and therapy , 2013, CA: a cancer journal for clinicians.
[50] Yamuna Krishnan,et al. Two DNA nanomachines map pH changes along intersecting endocytic pathways inside the same cell. , 2013, Nature nanotechnology.
[51] Anusuya Banerjee,et al. Controlled release of encapsulated cargo from a DNA icosahedron using a chemical trigger. , 2013, Angewandte Chemie.
[52] Tomoko Emura,et al. RNA-templated DNA origami structures. , 2013, Chemical communications.
[53] M. Caligiuri,et al. Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties , 2013, The Journal of Immunology.
[54] V. Linko,et al. The enabled state of DNA nanotechnology. , 2013, Current opinion in biotechnology.
[55] Qiao Jiang,et al. DNA origami as an in vivo drug delivery vehicle for cancer therapy. , 2014, ACS nano.
[56] Björn Högberg,et al. Spatial control of membrane receptor function using ligand nanocalipers , 2014, Nature Methods.
[57] V. Petrenko,et al. Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein. , 2014, Nanomedicine : nanotechnology, biology, and medicine.
[58] T. G. Martin,et al. Facile and Scalable Preparation of Pure and Dense DNA Origami Solutions , 2014, Angewandte Chemie.
[59] Stephanie A. Morris,et al. Nanotechnologies in cancer treatment and diagnosis. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[60] J. Cortes,et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. , 2014, Blood.
[61] William M. Shih,et al. Virus-Inspired Membrane Encapsulation of DNA Nanostructures To Achieve In Vivo Stability , 2014, ACS nano.
[62] John C Kraft,et al. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. , 2014, Journal of pharmaceutical sciences.
[63] J. Kjems,et al. Quantification of cellular uptake of DNA nanostructures by qPCR. , 2014, Methods.
[64] Tao Zhang,et al. Hierarchical assembly of metal nanoparticles, quantum dots and organic dyes using DNA origami scaffolds. , 2013, Nature nanotechnology.
[65] H. Su,et al. DNA origami compliant nanostructures with tunable mechanical properties. , 2014, ACS nano.
[66] William M. Shih,et al. Addressing the Instability of DNA Nanostructures in Tissue Culture , 2014, ACS nano.
[67] Johannes B. Woehrstein,et al. Multiplexed 3D Cellular Super-Resolution Imaging with DNA-PAINT and Exchange-PAINT , 2014, Nature Methods.
[68] R. Srivastava,et al. Nanodrug delivery in reversing multidrug resistance in cancer cells , 2014, Front. Pharmacol..
[69] G. Nienhaus,et al. Engineered nanoparticles interacting with cells: size matters , 2014, Journal of Nanobiotechnology.
[70] Jarno Salonen,et al. Inhibition of Multidrug Resistance of Cancer Cells by Co‐Delivery of DNA Nanostructures and Drugs Using Porous Silicon Nanoparticles@Giant Liposomes , 2015 .